RenovoCyte, LLC Signs Exclusive License Agreement for Veterinary Applications of Endometrial Regenerative Cells with Medistem
RenovoCyte, LLC. announced it has entered into a license agreement with Medistem, Inc. to develop and commercialize cellular therapy based on Medistem's proprietary universal donor endometrial regenerative cells (ERC) for use in veterinary applications.
"This partnership represents a unique collaboration in that Medistem's ERC technology has already been used to treat humans." Said Dr. Shelly Zacharias, Director of Veterinary Operations of RenovoCyte. "In this case much of what has been learned in humans will be adapted to animals to make an off-the-shelf product to put cellular medicine into the hands of every veterinarian."
"Since we originally reported the discovery of Endometrial Regenerative Cells in 2007, at least 4 independent groups have used and published on cells with identical or near-identical properties to treat animals with diabetes, Parkinson's, stroke, and heart failure." Said Dr. Vladimir Bogin, Chairman and President of Medistem.
"It was an ideal fit to work with Medistem to commercialize ERCs in the veterinary space." Said Dr. Erik Woods, President and CEO of RenovoCyte LLC. "Given their intellectual property position on these cells, combined with our extensive experience with cell manufacture and logistics, we are confident that we will accelerate our own development efforts in veterinary medicine, as well as advance the field of cell therapy forward."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
